Optimizing the Boosting Schedule of Subunit Vaccines Consisting of BCG and "Non-BCG" Antigens to Induce Long-Term Immune Memory

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2022 May 2

PMID 35493466

Authors

Wei Lv

Pu He

Yanlin Ma

Daquan Tan

Fei Li

Tao Xie

Jiangyuan Han

Juan Wang

Youjun Mi

Hongxia Niu

Bingdong Zhu

Affiliations

Soon will be listed here.

Abstract

Boosting Bacillus Calmette-Guérin (BCG) with subunit vaccine is expected to induce long-term protection against tuberculosis (TB). However, it is urgently needed to optimize the boosting schedule of subunit vaccines, which consists of antigens from or not from BCG, to induce long-term immune memory. To address it two subunit vaccines, Mtb10.4-HspX (MH) consisting of BCG antigens and ESAT6-CFP10 (EC) consisting of antigens from the region of difference (RD) of (), were applied to immunize BCG-primed C57BL/6 mice twice or thrice with different intervals, respectively. The long-term antigen-specific immune responses and protective efficacy against H37Ra were determined. The results showed that following BCG priming, MH boosting twice at 12-24 weeks or EC immunizations thrice at 12-16-24 weeks enhanced the number and function of long-lived memory T cells with improved protection against H37Ra, while MH boosting thrice at 12-16-24 weeks or twice at 8-14 weeks and EC immunizations twice at 12-24 weeks or thrice at 8-10-14 weeks didn't induce long-term immunity. It suggests that following BCG priming, both BCG antigens MH boosting twice and "non-BCG" antigens EC immunizations thrice at suitable intervals induce long-lived memory T cell-mediated immunity.

Citing Articles

Enhancing cell-mediated immunity through dendritic cell activation: the role of Tri-GalNAc-modified PLGA-PEG nanoparticles encapsulating SR717.

Gong Y, Jia H, Dang W, Zhou T, He P, Wang X Front Immunol. 2025; 15:1490003.

PMID: 39763671 PMC: 11701044. DOI: 10.3389/fimmu.2024.1490003.

The combination of fusion proteins LT33 and LT28 induced strong protective immunity in mice.

He P, Wang J, Tan D, Hu L, Ma Y, Mi Y Front Immunol. 2024; 15:1450124.

PMID: 39650665 PMC: 11621036. DOI: 10.3389/fimmu.2024.1450124.

DNA and RNA vaccines against tuberculosis: a scoping review of human and animal studies.

Kazakova A, Zhelnov P, Sidorov R, Rogova A, Vasileva O, Ivanov R Front Immunol. 2024; 15:1457327.

PMID: 39421744 PMC: 11483866. DOI: 10.3389/fimmu.2024.1457327.

Intranasal vaccination with engineered BCG expressing CCL2 induces a stronger immune barrier against Mycobacterium tuberculosis than BCG.

Guo S, Ouyang J, Hu Z, Cao T, Huang C, Mou J Mol Ther. 2024; 32(11):3990-4005.

PMID: 39295146 PMC: 11573603. DOI: 10.1016/j.ymthe.2024.09.021.

Tuberculosis Vaccines and T Cell Immune Memory.

Li F, Dang W, Du Y, Xu X, He P, Zhou Y Vaccines (Basel). 2024; 12(5).

PMID: 38793734 PMC: 11125691. DOI: 10.3390/vaccines12050483.

References

Xin Q, Niu H, Li Z, Zhang G, Hu L, Wang B . Subunit vaccine consisting of multi-stage antigens has high protective efficacy against Mycobacterium tuberculosis infection in mice. PLoS One. 2013; 8(8):e72745. PMC: 3744459. DOI: 10.1371/journal.pone.0072745. View

Costa Del Amo P, Lahoz-Beneytez J, Boelen L, Ahmed R, Miners K, Zhang Y . Human TSCM cell dynamics in vivo are compatible with long-lived immunological memory and stemness. PLoS Biol. 2018; 16(6):e2005523. PMC: 6033534. DOI: 10.1371/journal.pbio.2005523. View

Gattinoni L, Speiser D, Lichterfeld M, Bonini C . T memory stem cells in health and disease. Nat Med. 2017; 23(1):18-27. PMC: 6354775. DOI: 10.1038/nm.4241. View

Idoko O, Owolabi O, Owiafe P, Moris P, Odutola A, Bollaerts A . Safety and immunogenicity of the M72/AS01 candidate tuberculosis vaccine when given as a booster to BCG in Gambian infants: an open-label randomized controlled trial. Tuberculosis (Edinb). 2014; 94(6):564-78. DOI: 10.1016/j.tube.2014.07.001. View

Nemes E, Geldenhuys H, Rozot V, Rutkowski K, Ratangee F, Bilek N . Prevention of M. tuberculosis Infection with H4:IC31 Vaccine or BCG Revaccination. N Engl J Med. 2018; 379(2):138-149. PMC: 5937161. DOI: 10.1056/NEJMoa1714021. View

Fatma F, Tripathi D, Srivastava M, Srivastava K, Arora A . Immunological characterization of chimeras of high specificity antigens from Mycobacterium tuberculosis H37Rv. Tuberculosis (Edinb). 2021; 127:102054. DOI: 10.1016/j.tube.2021.102054. View

Andersen P, Doherty T . The success and failure of BCG - implications for a novel tuberculosis vaccine. Nat Rev Microbiol. 2005; 3(8):656-62. DOI: 10.1038/nrmicro1211. View

Furin J, Cox H, Pai M . Tuberculosis. Lancet. 2019; 393(10181):1642-1656. DOI: 10.1016/S0140-6736(19)30308-3. View

Nandakumar S, Kannanganat S, Dobos K, Lucas M, Spencer J, Fang S . O-mannosylation of the Mycobacterium tuberculosis adhesin Apa is crucial for T cell antigenicity during infection but is expendable for protection. PLoS Pathog. 2013; 9(10):e1003705. PMC: 3795050. DOI: 10.1371/journal.ppat.1003705. View

10.

Bhattacharya D, Dwivedi V, Kumar S, Reddy M, Van Kaer L, Moodley P . Simultaneous inhibition of T helper 2 and T regulatory cell differentiation by small molecules enhances Bacillus Calmette-Guerin vaccine efficacy against tuberculosis. J Biol Chem. 2014; 289(48):33404-11. PMC: 4246096. DOI: 10.1074/jbc.M114.600452. View

11.

Klebanoff C, Gattinoni L, Torabi-Parizi P, Kerstann K, Cardones A, Finkelstein S . Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. Proc Natl Acad Sci U S A. 2005; 102(27):9571-6. PMC: 1172264. DOI: 10.1073/pnas.0503726102. View

12.

Grode L, Seiler P, Baumann S, Hess J, Brinkmann V, Eddine A . Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guérin mutants that secrete listeriolysin. J Clin Invest. 2005; 115(9):2472-9. PMC: 1187936. DOI: 10.1172/JCI24617. View

13.

Tameris M, Hatherill M, Landry B, Scriba T, Snowden M, Lockhart S . Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet. 2013; 381(9871):1021-8. PMC: 5424647. DOI: 10.1016/S0140-6736(13)60177-4. View

14.

Masopust D, Vezys V, Marzo A, Lefrancois L . Preferential localization of effector memory cells in nonlymphoid tissue. Science. 2001; 291(5512):2413-7. DOI: 10.1126/science.1058867. View

15.

Nandakumar S, Kannanganat S, Dobos K, Lucas M, Spencer J, Amara R . Boosting BCG-primed responses with a subunit Apa vaccine during the waning phase improves immunity and imparts protection against Mycobacterium tuberculosis. Sci Rep. 2016; 6:25837. PMC: 4865829. DOI: 10.1038/srep25837. View

16.

Achkar J, Prados-Rosales R . Updates on antibody functions in Mycobacterium tuberculosis infection and their relevance for developing a vaccine against tuberculosis. Curr Opin Immunol. 2018; 53:30-37. PMC: 6141321. DOI: 10.1016/j.coi.2018.04.004. View

17.

Tonaco M, Moreira J, Nunes F, Loures C, Souza L, Martins J . Evaluation of profile and functionality of memory T cells in pulmonary tuberculosis. Immunol Lett. 2017; 192:52-60. DOI: 10.1016/j.imlet.2017.10.014. View

18.

Lindenstrom T, Knudsen N, Agger E, Andersen P . Control of chronic mycobacterium tuberculosis infection by CD4 KLRG1- IL-2-secreting central memory cells. J Immunol. 2013; 190(12):6311-9. DOI: 10.4049/jimmunol.1300248. View

19.

Reed S, Coler R, Dalemans W, Dalemans W, Tan E, Dela Cruz E . Defined tuberculosis vaccine, Mtb72F/AS02A, evidence of protection in cynomolgus monkeys. Proc Natl Acad Sci U S A. 2009; 106(7):2301-6. PMC: 2650151. DOI: 10.1073/pnas.0712077106. View

20.

Wherry E, Barber D, Kaech S, Blattman J, Ahmed R . Antigen-independent memory CD8 T cells do not develop during chronic viral infection. Proc Natl Acad Sci U S A. 2004; 101(45):16004-9. PMC: 524220. DOI: 10.1073/pnas.0407192101. View